Insmed reported $2.1B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
DBV Technologies USD 223.2M 43.2M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026